{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:38:47Z","timestamp":1773797927461,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00415-026-13663-x","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T15:45:00Z","timestamp":1770306300000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A patient with anti-IgLON5 disease associated with cerebral hemorrhage, multiple ischemic strokes, and kidney failure: case report"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8054-4313","authenticated-orcid":false,"given":"Valeria","family":"Sajin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moritz Philipp","family":"B\u00f6hringer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus-Peter","family":"Wandinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swantje","family":"Mindorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernst Ulrich","family":"Walther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"issue":"8","key":"13663_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0104082","volume":"9","author":"M Sabater-Lleal","year":"2014","unstructured":"Sabater-Lleal M, Malarstig A, Folkersen L et al (2014) Common genetic determinants of lung function, subclinical atherosclerosis and risk of coronary artery disease. PLoS One 9(8):e104082. https:\/\/doi.org\/10.1371\/journal.pone.0104082","journal-title":"PLoS One"},{"issue":"5","key":"13663_CR2","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.4103\/1673-5374.355742","volume":"18","author":"YH Zhang","year":"2023","unstructured":"Zhang YH, Ni Y, Gao YN et al (2023) Anti-IgLON5 disease: a novel topic beyond neuroimmunology. Neural Regen Res. 18(5):1017\u20131022. https:\/\/doi.org\/10.4103\/1673-5374.355742","journal-title":"Neural Regen Res."},{"issue":"2","key":"13663_CR3","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/brain\/awac090","volume":"146","author":"T Gruter","year":"2023","unstructured":"Gruter T, Mollers FE, Tietz A et al (2023) Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease. Brain 146(2):600\u2013611. https:\/\/doi.org\/10.1093\/brain\/awac090","journal-title":"Brain"},{"issue":"18","key":"13663_CR4","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1212\/WNL.0000000000003887","volume":"88","author":"C Gaig","year":"2017","unstructured":"Gaig C, Graus F, Compta Y et al (2017) Clinical manifestations of the anti-IgLON5 disease. Neurology 88(18):1736\u20131743. https:\/\/doi.org\/10.1212\/WNL.0000000000003887","journal-title":"Neurology"},{"issue":"7","key":"13663_CR5","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1093\/brain\/awae048","volume":"147","author":"SM Yogeshwar","year":"2024","unstructured":"Yogeshwar SM, Muniz-Castrillo S, Sabater L et al (2024) HLA-DQB1*05 subtypes and not DRB1*10:01 mediates risk in anti-IgLON5 disease. Brain 147(7):2579\u20132592. https:\/\/doi.org\/10.1093\/brain\/awae048","journal-title":"Brain"},{"key":"13663_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2018.00008","volume":"11","author":"K Karis","year":"2018","unstructured":"Karis K, Eskla KL, Kaare M et al (2018) Altered expression profile of IgLON family of neural cell adhesion molecules in the dorsolateral prefrontal cortex of schizophrenic patients. Front Mol Neurosci 11:8. https:\/\/doi.org\/10.3389\/fnmol.2018.00008","journal-title":"Front Mol Neurosci"},{"key":"13663_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25147956","author":"J Andersen","year":"2024","unstructured":"Andersen J, Jeffrey B, Varikatt W, Rodriguez M, Lin MW, Brown DA (2024) IgLON5-IgG: innocent bystander or perpetrator? Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25147956","journal-title":"Int J Mol Sci"},{"issue":"7","key":"13663_CR8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208101","volume":"102","author":"C Gaig","year":"2024","unstructured":"Gaig C, Gruter T, Heidbreder A et al (2024) Development of a composite score for the clinical assessment of anti-IgLON5 disease. Neurology 102(7):e208101. https:\/\/doi.org\/10.1212\/WNL.0000000000208101","journal-title":"Neurology"},{"key":"13663_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.852215","volume":"13","author":"N Madetko","year":"2022","unstructured":"Madetko N, Marzec W, Kowalska A, Przewodowska D, Alster P, Koziorowski D (2022) Anti-IgLON5 disease - the current state of knowledge and further perspectives. Front Immunol 13:852215. https:\/\/doi.org\/10.3389\/fimmu.2022.852215","journal-title":"Front Immunol"},{"issue":"14","key":"13663_CR10","doi-asserted-by":"publisher","first-page":"e1367","DOI":"10.1212\/WNL.0000000000012639","volume":"97","author":"C Gaig","year":"2021","unstructured":"Gaig C, Compta Y, Heidbreder A et al (2021) Frequency and characterization of movement disorders in anti-IgLON5 disease. Neurology 97(14):e1367\u2013e1381. https:\/\/doi.org\/10.1212\/WNL.0000000000012639","journal-title":"Neurology"},{"issue":"3","key":"13663_CR11","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/WCO.0000000000001271","volume":"37","author":"C Gaig","year":"2024","unstructured":"Gaig C, Sabater L (2024) New knowledge on anti-IgLON5 disease. Curr Opin Neurol 37(3):316\u2013321. https:\/\/doi.org\/10.1097\/WCO.0000000000001271","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"13663_CR12","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200353","volume":"12","author":"F Graus","year":"2025","unstructured":"Graus F, Sabater L, Gaig C, Gelpi E, Iranzo A, Dalmau JO, Santamaria J (2025) Anti-IgLON5 disease 10 years later: what we know and what we do not know. Neurol Neuroimmunol Neuroinflamm 12(1):e200353. https:\/\/doi.org\/10.1212\/NXI.0000000000200353","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"13663_CR13","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.otoeng.2024.04.001","volume":"75","author":"D Pastene","year":"2024","unstructured":"Pastene D, Lehrer E, Jubes S et al (2024) Upper airway manifestations of anti-IgLON5 disease: otorhinolaryngological point of view. Acta Otorrinolaringologica (English Edition) 75(5):288\u2013295. https:\/\/doi.org\/10.1016\/j.otoeng.2024.04.001","journal-title":"Acta Otorrinolaringologica (English Edition)"},{"issue":"7","key":"13663_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-018-0848-0","volume":"18","author":"C Gaig","year":"2018","unstructured":"Gaig C, Iranzo A, Santamaria J, Graus F (2018) The sleep disorder in anti-lgLON5 disease. Curr Neurol Neurosci Rep 18(7):41. https:\/\/doi.org\/10.1007\/s11910-018-0848-0","journal-title":"Curr Neurol Neurosci Rep"},{"key":"13663_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2022.577999","volume":"373","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wang Y, Zhao X et al (2022) Epileptic seizures in patients with anti-IgLON5 disease. J Neuroimmunol 373:577999. https:\/\/doi.org\/10.1016\/j.jneuroim.2022.577999","journal-title":"J Neuroimmunol"},{"key":"13663_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.800298","volume":"13","author":"Y Fu","year":"2022","unstructured":"Fu Y, Zou X, Liu L (2022) Epileptic seizures and right-sided hippocampal swelling as presenting symptoms of anti-IgLON5 disease: a case report and systematic review of the literature. Front Neurol 13:800298. https:\/\/doi.org\/10.3389\/fneur.2022.800298","journal-title":"Front Neurol"},{"key":"13663_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.632497","volume":"12","author":"J El Shazly","year":"2021","unstructured":"El Shazly J, Juenemann M, Gerriets T, Tschernatsch M (2021) Case report: neuropsychological findings in IgLON5 antibody disorder. Front Neurol 12:632497. https:\/\/doi.org\/10.3389\/fneur.2021.632497","journal-title":"Front Neurol"},{"issue":"1","key":"13663_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.8310","volume":"12","author":"Y Luo","year":"2024","unstructured":"Luo Y, Xiao J, Li J (2024) The psychiatric symptoms in anti-IgLON5 disease: case report and literature review. Clin Case Rep 12(1):e8310. https:\/\/doi.org\/10.1002\/ccr3.8310","journal-title":"Clin Case Rep"},{"issue":"15","key":"13663_CR19","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.2169\/internalmedicine.2865-23","volume":"63","author":"D Sato","year":"2024","unstructured":"Sato D, Sato H, Kondo T et al (2024) Anti-IgLON5 disease showing an improvement in dysautonomia, including vocal cord palsy, via combined immunotherapy. Intern Med 63(15):2187\u20132191. https:\/\/doi.org\/10.2169\/internalmedicine.2865-23","journal-title":"Intern Med"},{"key":"13663_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.106992","volume":"124","author":"Y Ono","year":"2024","unstructured":"Ono Y, Tadokoro K, Yunoki T et al (2024) Anti-IgLON5 disease as a differential diagnosis of multiple system atrophy. Parkinsonism Relat Disord 124:106992. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.106992","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"13663_CR21","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/mdc3.12407","volume":"4","author":"T Montojo","year":"2017","unstructured":"Montojo T, Piren V, Benkhadra F, Codreanu A, Diederich NJ (2017) Gaze palsy, sleep and gait disorder, as well as Tako-Tsubo syndrome in a patient with IgLON5 antibodies. Mov Disord Clin Pract 4(3):441\u2013443. https:\/\/doi.org\/10.1002\/mdc3.12407","journal-title":"Mov Disord Clin Pract"},{"key":"13663_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112088","volume":"142","author":"W Xiong","year":"2021","unstructured":"Xiong W, Feng S, Wang H et al (2021) Identification of candidate genes and pathways in limonin-mediated cardiac repair after myocardial infarction. Biomed Pharmacother 142:112088. https:\/\/doi.org\/10.1016\/j.biopha.2021.112088","journal-title":"Biomed Pharmacother"},{"key":"13663_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00576","volume":"11","author":"N Hansen","year":"2020","unstructured":"Hansen N, Hirschel S, Stocker W et al (2020) Figural memory impairment in conjunction with neuropsychiatric symptoms in IgLON5 antibody-associated autoimmune encephalitis. Front Psychiatry 11:576. https:\/\/doi.org\/10.3389\/fpsyt.2020.00576","journal-title":"Front Psychiatry"},{"issue":"5","key":"13663_CR24","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000385","volume":"4","author":"JA Honorat","year":"2017","unstructured":"Honorat JA, Komorowski L, Josephs KA et al (2017) IgLON5 antibody: neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm 4(5):e385. https:\/\/doi.org\/10.1212\/NXI.0000000000000385","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13663_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.01056","volume":"10","author":"MS Nissen","year":"2019","unstructured":"Nissen MS, Blaabjerg M (2019) Anti-IgLON5 disease: a case with 11-year clinical course and review of the literature. Front Neurol 10:1056. https:\/\/doi.org\/10.3389\/fneur.2019.01056","journal-title":"Front Neurol"},{"key":"13663_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.0523","author":"S Hasan","year":"2025","unstructured":"Hasan S, Dubey D, Aksamit A (2025) Tongue myokymia in IgLON5-IgG autoimmunity. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2025.0523","journal-title":"JAMA Neurol"},{"issue":"2","key":"13663_CR27","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3233\/JAD-201105","volume":"79","author":"M Tagliapietra","year":"2021","unstructured":"Tagliapietra M, Frasson E, Cardellini D et al (2021) Hypothalamic-bulbar MRI hyperintensity in anti-IgLON5 disease with serum-restricted antibodies: a case report and systematic review of literature. J Alzheimers Dis 79(2):683\u2013691. https:\/\/doi.org\/10.3233\/JAD-201105","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"13663_CR28","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1001\/jamaneurol.2019.3638","volume":"77","author":"H Chen","year":"2020","unstructured":"Chen H, Wu J, Irani SR (2020) Distinctive magnetic resonance imaging findings in IgLON5 antibody disease. JAMA Neurol 77(1):125\u2013126. https:\/\/doi.org\/10.1001\/jamaneurol.2019.3638","journal-title":"JAMA Neurol"},{"key":"13663_CR29","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001137","author":"C Strippel","year":"2022","unstructured":"Strippel C, Heidbreder A, Schulte-Mecklenbeck A et al (2022) Increased intrathecal B and plasma cells in patients with anti-IgLON5 disease: a case series. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000001137","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"13663_CR30","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000485","volume":"5","author":"VK Ramanan","year":"2018","unstructured":"Ramanan VK, Crum BA, McKeon A (2018) Subacute encephalitis with recovery in IgLON5 autoimmunity. Neurol Neuroimmunol Neuroinflamm 5(5):e485. https:\/\/doi.org\/10.1212\/NXI.0000000000000485","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"13663_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-022-03044-y","volume":"23","author":"Y Li","year":"2023","unstructured":"Li Y, Zhang L, Wang Y (2023) Anti-IgLON5 disease complicated with rectal adenocarcinoma: a case report. BMC Neurol 23(1):1. https:\/\/doi.org\/10.1186\/s12883-022-03044-y","journal-title":"BMC Neurol"},{"issue":"4","key":"13663_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-025-13001-7","volume":"272","author":"A Farina","year":"2025","unstructured":"Farina A, Villagran-Garcia M, Abichou-Klich A et al (2025) Application of the anti-IgLON5 disease composite score to assess severity, clinical course, and mortality in a French cohort. J Neurol 272(4):273. https:\/\/doi.org\/10.1007\/s00415-025-13001-7","journal-title":"J Neurol"},{"issue":"4","key":"13663_CR33","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/ane.13207","volume":"141","author":"P Cabezudo-Garcia","year":"2020","unstructured":"Cabezudo-Garcia P, Mena-Vazquez N, Estivill Torrus G, Serrano-Castro P (2020) Response to immunotherapy in anti-IgLON5 disease: a systematic review. Acta Neurol Scand 141(4):263\u2013270. https:\/\/doi.org\/10.1111\/ane.13207","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"13663_CR34","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000577","volume":"6","author":"V Brunetti","year":"2019","unstructured":"Brunetti V, Della Marca G, Spagni G, Iorio R (2019) Immunotherapy improves sleep and cognitive impairment in anti-IgLON5 encephalopathy. Neurol Neuroimmunol Neuroinflamm 6(4):e577. https:\/\/doi.org\/10.1212\/NXI.0000000000000577","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13663_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1340284","volume":"15","author":"Y Chen","year":"2024","unstructured":"Chen Y, Chen J, Pei Z, Qian W (2024) Atypical neurological manifestations in anti-IgLON5 disease: a case report. Front Neurol 15:1340284. https:\/\/doi.org\/10.3389\/fneur.2024.1340284","journal-title":"Front Neurol"},{"key":"13663_CR36","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.2574","author":"T Gr\u00fcter","year":"2025","unstructured":"Gr\u00fcter T, Gaig C, Crijnen YS, Titulaer MJ, Sabater L, Heidbreder A, Dargvainiene J, Tietz A, Kovac S, Dik A, Erro ME, Lewerenz J, Kraft A, Seifert F, H\u00f6ftberger R, Thaler FS, de Azevedo L, Wickel J, de Vries JM, Boon AJW, van Steenhoven RW, Gold R, Wandinger KP, Kuhlenb\u00e4umer G, Dalmau JO, Leypoldt F, Graus F, Ayzenberg I (2025) Early treatment with intravenous immunoglobulins and outcomes of patients with anti-IgLON5 disease. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2025.2574","journal-title":"JAMA Neurol"},{"issue":"9","key":"13663_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci15090921","volume":"15","author":"T Howischer","year":"2025","unstructured":"Howischer T, Gattermeyer-Kell L, Hirschbichler S, Seifert-Held T, Br\u00e4sen JH, Katschnig-Winter P, K\u00f6gl M, Franthal S, Enzinger C, H\u00f6ftberger R, Schwingenschuh P (2025) Causes of death in anti-IgLON5 disease: a novel case report and systematic literature review. Brain Sci 15(9):921. https:\/\/doi.org\/10.3390\/brainsci15090921","journal-title":"Brain Sci"},{"issue":"5","key":"13663_CR38","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000385","volume":"4","author":"JA Honorat","year":"2017","unstructured":"Honorat JA, Komorowski L, Josephs KA, Fechner K, St Louis EK, Hinson SR, Lederer S, Kumar N, Gadoth A, Lennon VA, Pittock SJ, McKeon A (2017) IgLON5 antibody: neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm 4(5):e385. https:\/\/doi.org\/10.1212\/NXI.0000000000000385","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"18","key":"13663_CR39","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1212\/WNL.0000000000003887","volume":"88","author":"C Gaig","year":"2017","unstructured":"Gaig C, Graus F, Compta Y, H\u00f6gl B, Bataller L, Br\u00fcggemann N, Giordana C, Heidbreder A, Kotschet K, Lewerenz J, Macher S, Mart\u00ed MJ, Montojo T, P\u00e9rez-P\u00e9rez J, Puertas I, Seitz C, Simabukuro M, T\u00e9llez N, Wandinger KP, Iranzo A, Ercilla G, Sabater L, Santamar\u00eda J, Dalmau J (2017) Clinical manifestations of the anti-IgLON5 disease. Neurology 88(18):1736\u20131743. https:\/\/doi.org\/10.1212\/WNL.0000000000003887","journal-title":"Neurology"},{"key":"13663_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1151574","volume":"14","author":"J Landa","year":"2023","unstructured":"Landa J, Serafim AB, Gaig C, Saiz A, Koneczny I, Hoftberger R, Santamaria J, Dalmau J, Graus F, Sabater L (2023) Patients\u2019 IgLON5 autoantibodies interfere with IgLON5-protein interactions. Front Immunol 14:1151574. https:\/\/doi.org\/10.3389\/fimmu.2023.1151574","journal-title":"Front Immunol"},{"issue":"7","key":"13663_CR41","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1007\/s00415-020-09924-y","volume":"267","author":"T Gr\u00fcter","year":"2020","unstructured":"Gr\u00fcter T, Behrendt V, Bien CI, Gold R, Ayzenberg I (2020) Early immunotherapy is highly effective in IgG1\/IgG4 positive IgLON5 disease. J Neurol 267(7):2151\u20132153. https:\/\/doi.org\/10.1007\/s00415-020-09924-y","journal-title":"J Neurol"},{"key":"13663_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2025.123463","volume":"472","author":"M Furlepa","year":"2025","unstructured":"Furlepa M, Astin R, Fishman J, Saifee T (2025) Ventilation and tracheostomy insertion in anti-IgLON5 disease: a systematic review of cases. J Neurol Sci 472:123463. https:\/\/doi.org\/10.1016\/j.jns.2025.123463","journal-title":"J Neurol Sci"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13663-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13663-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13663-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T22:03:25Z","timestamp":1773785005000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13663-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["13663"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13663-x","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest related to the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"AI and AI-assisted technologies were\n                      not\n                      used in the writing process.\n                      Ethical Compliance Statement\n                      The authors confirm that the approval of an institutional review board was not required for this work. Patient consent was obtained for this publication. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of generative AI in scientific writing"}}],"article-number":"116"}}